Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2026-04-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于公司及控股公司向金融机构申请授信额度及公司合并报表范围内担保额度的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's and its subsidiaries' application for credit facilities from financial institutions and the provision of guarantee limits within the consolidated financial statements. It includes specific financial figures, guarantee amounts, ratios relative to audited net assets, and detailed information about the subsidiaries involved. The document also mentions board resolutions and the need for shareholder approval at the 2025 annual general meeting. The content focuses on financing and guarantee arrangements rather than presenting full financial statements or audit opinions. It is not a full annual or interim report, nor is it a simple announcement of a report publication. The document is a formal announcement about capital/financing activities, specifically credit and guarantee limits, which fits the Capital/Financing Update category.
2026-04-23 Chinese
关于开展外汇套期保值业务的可行性分析报告
Regulatory Filings Classification · 90% confidence The document is a detailed feasibility analysis report on the company's plan to conduct foreign exchange hedging business. It discusses the background, necessity, scope, risk analysis, and risk management measures related to foreign exchange derivative transactions. It is not a financial report like an annual or interim report, nor is it an announcement of voting results, management changes, or legal proceedings. It is a specific report analyzing the feasibility of a financial risk management activity. This type of document does not fit into categories like regulatory filings or announcements but is a standalone report on a specific financial strategy. Given the nature of the content, it best fits under Regulatory Filings (RNS) as a miscellaneous regulatory disclosure that does not fit other categories.
2026-04-23 Chinese
关于审计委员会对会计师事务所2025年度履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Audit Committee regarding the supervision of the accounting firm (立信会计师事务所) for the company's 2025 audit. It details the audit firm's qualifications, the committee's oversight activities, meetings held, and the audit process for the 2025 fiscal year. The document does not contain the full audit report or financial statements but rather a supervisory report on the audit firm's performance and oversight. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory oversight related to audits, excluding full annual reports. The document length is under 5,000 characters and is a detailed report, not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-23 Chinese
独立董事述职报告 （曾玉红）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025 for a listed company. It details the independent director's background, attendance at board and shareholder meetings, committee participation, communication with auditors, oversight of financial reports, and other governance-related activities. It is a detailed narrative report on the independent director's duties and observations during the year, rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it an announcement of voting results or a proxy statement. The content aligns with a management or board-related report focusing on governance and oversight activities by an independent director. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (4770 characters) is sufficient for a substantive report, not a brief announcement or certification.
2026-04-23 Chinese
独立董事述职报告 （刘梅娟）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025, authored by an independent director of the company. It details the director's activities, attendance at board and committee meetings, communication with internal audit, and oversight of financial reports and management appointments. The content focuses on the director's duties and performance rather than presenting financial statements or audit results. The document length is 3041 characters, which is relatively short and reads like a formal report or statement rather than a full financial or audit report. It does not contain financial data or detailed financial analysis. This type of document is best classified under Board/Management Information (MANG), as it relates to the activities and reports of a board member rather than a full annual report, audit report, or other financial filings.
2026-04-23 Chinese
薪酬与考核委员会议事规则（2026年4月修订）
Governance Information Classification · 100% confidence The document is titled '薪酬与考核委员会议事规则' which translates to 'Rules of Procedure for the Remuneration and Assessment Committee'. It details the structure, responsibilities, meeting procedures, and duties of the Remuneration and Assessment Committee of the company. The content focuses on governance aspects related to executive compensation and performance evaluation, including committee composition, meeting protocols, and decision-making processes. There are no financial statements, earnings data, or regulatory filings. This document is a governance-related internal rules document concerning remuneration and assessment committee operations, which fits the category of Governance Information (CGR).
2026-04-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.